The Food and Drug Administration approved the drug for use in combination with chemotherapy as a so-called second-line treatment for patients whose colorectal cancer has spread to other parts of the body.
The FDA granted Zaltrap “new molecular entity” status, which is reserved for drugs considered new and innovative chemical structures that previously haven’t been used in clinical practice. FDA grants each stand-alone biologic drug application new molecular entity status. Zaltrap will chemically be called ziv- aflibercept to distinguish it from Eylea.
The medicine is designed to control cancer growth by blocking the blood supply to the tumor. More than 143,000 new cases of colorectal cancer are likely to be diagnosed in the U. S. this year, according to the National Cancer Institute.
Colorectal cancer is the fourth most commonly diagnosed cancer and the fourth leading cause of cancer death in the U. S.